Bone Biologics Corporation (BBLG) Stock Forecast
BBLG analyst forecast
as of October 17, 2026- Analyst consensus
- —
- Price target
- $12.20 average of analyst targets
- Upside to target
- +2,988.6% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.19
- 52-week range
- $0.39 – $2.48
BBLG price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
BBLG earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.19 | −$0.37 | +48.6% | 1 |
| Current fiscal year (2026) | −$1.23 | −$1.23 | −$1.23 | −$2.65 | +53.6% | 1 |
| Next fiscal year (2027) | −$0.67 | −$0.67 | −$0.67 | −$1.23 | +45.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
BBLG revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
BBLG EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
BBLG EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.36 | −$0.36 | −$0.18 | −$0.18 | −$0.19 | −47.2% | 0 up · 1 down |
| Current fiscal year (2026) | −$1.93 | −$1.93 | −$1.17 | −$1.17 | −$1.23 | −36.3% | 0 up · 1 down |
| Next fiscal year (2027) | −$1.26 | −$1.26 | −$0.64 | −$0.64 | −$0.67 | −46.8% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
BBLG earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; BBLG beat in 8 of 12.
What analysts expect from BBLG
The average price target is $12.20, 2,988.6% above the latest close of $0.40. Analysts expect earnings of −$1.23 per share for 2026, +53.6% from a year earlier. For 2027 the average estimate is −$0.67 per share. Bone Biologics beat the EPS estimate in 8 of the last 12 quarters.
Related: BBLG income statement, BBLG key metrics, BBLG chart. See the BBLG stock overview for the latest quote and news.
BBLG forecast FAQ
What is Bone Biologics's price target?
The average analyst price target for Bone Biologics is $12.20, 2,988.6% above the latest close of $0.40.
What is Bone Biologics's EPS forecast?
Analysts forecast −$1.23 per share for 2026 (range −$1.23 to −$1.23); for 2027 the estimate is −$0.67.
When does Bone Biologics report earnings?
Bone Biologics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.19.
Does Bone Biologics usually beat earnings estimates?
Bone Biologics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.